[go: up one dir, main page]

LT3149019T - Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai - Google Patents

Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai

Info

Publication number
LT3149019T
LT3149019T LTEP15731260.4T LT15731260T LT3149019T LT 3149019 T LT3149019 T LT 3149019T LT 15731260 T LT15731260 T LT 15731260T LT 3149019 T LT3149019 T LT 3149019T
Authority
LT
Lithuania
Prior art keywords
tgr5
fxr
prevention
treatment
mediated diseases
Prior art date
Application number
LTEP15731260.4T
Other languages
English (en)
Inventor
Angela ZAMPELLA
Stefano Fiorucci
Original Assignee
Bar Pharmaceuticals S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bar Pharmaceuticals S.R.L. filed Critical Bar Pharmaceuticals S.R.L.
Publication of LT3149019T publication Critical patent/LT3149019T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
LTEP15731260.4T 2014-05-29 2015-05-28 Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai LT3149019T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITFI20140130 2014-05-29
PCT/EP2015/061802 WO2015181275A1 (en) 2014-05-29 2015-05-28 Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases

Publications (1)

Publication Number Publication Date
LT3149019T true LT3149019T (lt) 2020-02-25

Family

ID=51454763

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP19204247.1T LT3626725T (lt) 2014-05-29 2015-05-28 Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai
LTEP15731260.4T LT3149019T (lt) 2014-05-29 2015-05-28 Cholano dariniai, skirti naudoti fxr ir tgr5/gpbar1 medijuojamų ligų gydymui ir (arba) prevencijai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP19204247.1T LT3626725T (lt) 2014-05-29 2015-05-28 Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai

Country Status (25)

Country Link
US (2) US10407462B2 (lt)
EP (2) EP3149019B1 (lt)
JP (1) JP6820253B2 (lt)
KR (1) KR102491556B1 (lt)
CN (2) CN106661079B (lt)
AU (1) AU2015265893B2 (lt)
CA (1) CA2948585C (lt)
CY (1) CY1122631T1 (lt)
DK (2) DK3149019T3 (lt)
EA (1) EA032820B1 (lt)
ES (2) ES2768718T3 (lt)
FI (1) FI3626725T3 (lt)
HR (2) HRP20230170T1 (lt)
HU (2) HUE061506T2 (lt)
LT (2) LT3626725T (lt)
MA (1) MA39881B1 (lt)
MX (2) MX2020004024A (lt)
PH (1) PH12016502327A1 (lt)
PL (2) PL3149019T3 (lt)
PT (2) PT3149019T (lt)
RS (2) RS64050B1 (lt)
SG (2) SG11201609403UA (lt)
SI (2) SI3626725T1 (lt)
SM (2) SMT202300057T1 (lt)
WO (1) WO2015181275A1 (lt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
LT3626725T (lt) 2014-05-29 2023-03-10 Bar Pharmaceuticals S.R.L. Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai
WO2016045480A1 (zh) * 2014-09-28 2016-03-31 上海源力生物技术有限公司 一种奥贝胆酸的制备方法
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
CN111944006B (zh) * 2014-11-17 2021-12-17 正大天晴药业集团股份有限公司 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途
JP6724004B2 (ja) 2014-11-19 2020-07-15 エヌゼットピー ユーケー リミテッド ステロイドＦＸＲモジュレーター製造のための中間体としての５β−６−アルキル−７−ヒドロキシ−３−オンステロイド
MX381239B (es) 2014-11-19 2025-03-12 Nzp Uk Ltd Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
CA2968305A1 (en) 2014-11-19 2016-05-26 NZP UK Limited 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
BR112017010319B1 (pt) 2014-11-19 2023-04-11 NZP UK Limited Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
MX2017006833A (es) 2014-11-26 2018-02-13 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
SG11201706089RA (en) 2015-02-11 2017-09-28 Enanta Pharm Inc Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
SMT202100593T1 (it) 2015-03-31 2021-11-12 Enanta Pharm Inc Derivati degli acidi biliari come agonisti di fxr/tgr5 e metodi per il loro uso
DK3310801T3 (da) 2015-06-19 2021-06-21 Intercept Pharmaceuticals Inc Tgr5-modulatorer og fremgangsmåder til anvendelse deraf
WO2017053826A1 (en) * 2015-09-24 2017-03-30 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
WO2017147174A1 (en) * 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2017147159A1 (en) * 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
EA038632B1 (ru) * 2016-03-11 2021-09-27 Интерсепт Фармасьютикалз, Инк. 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr)
CN105859817A (zh) * 2016-05-09 2016-08-17 成都宇西医药技术有限公司 一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
WO2017207648A1 (en) 2016-05-31 2017-12-07 Bionice, S.L.U Process and intermediates for the preparation of obeticholic acid and derivatives thereof
EP3464316A4 (en) 2016-06-01 2020-02-19 Dr. Reddy's Laboratories Ltd. PROCESS FOR THE PREPARATION OF OBETICHOLIC ACID
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
MX2018015443A (es) 2016-06-13 2019-04-11 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
IT201600068742A1 (it) * 2016-07-01 2018-01-01 Bar Pharmaceuticals Soc A Responsabilita Limitata Derivati dell'acido iodesossicolico e loro uso
CA3045023A1 (en) 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
AU2018243719B2 (en) 2017-03-28 2021-01-21 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
AU2018249950B2 (en) * 2017-04-07 2023-09-21 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CN109021054B (zh) * 2017-06-09 2021-04-09 博瑞生物医药（苏州）股份有限公司 一种fxr激动剂
CN109021055B (zh) * 2017-06-09 2021-04-09 博瑞生物医药（苏州）股份有限公司 Fxr激动剂
CN109021056B (zh) * 2017-06-09 2021-03-09 博瑞生物医药（苏州）股份有限公司 法尼酯x受体激动剂
EP3660030A4 (en) * 2017-07-26 2021-04-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. METHOD OF MANUFACTURING STEROID-DERIVATIVE FXR AGONISTS
WO2019085963A1 (zh) * 2017-11-02 2019-05-09 正大天晴药业集团股份有限公司 一种胆酸类化合物的制备方法
CA3124702A1 (en) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
CN112824425B (zh) * 2019-11-21 2023-10-03 成都西岭源药业有限公司 一种6-位烯基取代胆酸化合物及其制备方法和应用
JP2023516187A (ja) 2020-02-28 2023-04-18 キャリーオペ，インク． Ｇｐｒ４０アゴニスト
IT202000008515A1 (it) 2020-04-21 2021-10-21 Bar Pharmaceuticals Soc A Responsabilita Limitata Metodo per la sintesi di un derivato del colano
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
IT202200011705A1 (it) * 2022-06-01 2023-12-01 Prec Bio Therapeutics S R L Derivati del colesterolo e loro usi
WO2024006537A1 (en) * 2022-07-01 2024-01-04 Intercept Pharmaceuticals, Inc. Methods for ameliorating cognitive impairment using bile acid derivatives
IT202200018669A1 (it) 2022-09-13 2024-03-13 Bar Pharmaceuticals Soc A Responsabilita Limitata Combinazioni farmaceutiche comprendenti derivati del colano e loro usi
WO2024097247A1 (en) * 2022-10-31 2024-05-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2024195903A1 (ko) * 2023-03-21 2024-09-26 경희대학교 산학협력단 신규한 콜린산 유도체 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2356887A1 (en) * 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
IL157816A0 (en) * 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
PT1734970E (pt) * 2004-03-12 2015-03-11 Intercept Pharmaceuticals Inc Tratamento de fibrose utilizando ligandos de rfx
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US7932244B2 (en) 2006-06-27 2011-04-26 Intercept Pharmaceuticals, Inc. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
US8940719B2 (en) * 2006-07-03 2015-01-27 Academia Sinica Lithocholic acid analogues that inhibit sialyltransferase
FR2908310B1 (fr) * 2006-11-14 2009-07-10 Phytodia Produits agonistes de tgr5 et leurs applications
EA017714B1 (ru) * 2007-01-19 2013-02-28 Интерсепт Фармасьютикалз, Инк. Модуляторы tgr5 и способы их применения
EP1947108A1 (en) * 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
AU2009316566B9 (en) * 2008-11-19 2014-05-15 Intercept Pharmaceuticals, Inc. TGR5 modulators and method of use thereof
EP3150620B1 (en) * 2008-11-19 2020-01-08 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
WO2012047495A2 (en) * 2010-09-27 2012-04-12 Kythera Biopharmaceuticals, Inc. Methods for preparing synthetic bile acids and compositions comprising the same
CA2842707A1 (en) 2011-08-04 2013-02-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pancreatitis
KR20190121871A (ko) * 2012-06-19 2019-10-28 인터셉트 파마슈티컬즈, 인크. 오베티콜산의 제조법, 용도 및 고체 형태
EP2912013B1 (en) * 2012-10-26 2017-10-11 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
CN103143021A (zh) * 2013-03-21 2013-06-12 中国药科大学 PPARα-UGT通路抑制剂在治疗炎性肠疾病中的应用
CN108245523B (zh) * 2013-05-14 2021-03-26 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11-羟基衍生物及其氨基酸共轭物
CN110437297B9 (zh) * 2013-08-01 2022-01-11 美国卫生和人力服务部 法尼醇x受体的抑制剂和在医学中的用途
US10166246B2 (en) * 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
LT3626725T (lt) 2014-05-29 2023-03-10 Bar Pharmaceuticals S.R.L. Cholano dariniai skirti naudoti ligų, kurių atsiradimui tarpininkauja fxr ir tgr5/gpbar1, gydymui ir (arba) profilaktikai
US20170233431A1 (en) * 2016-02-17 2017-08-17 City Of Hope Bile acid derivatives and methods for synthesis and use

Also Published As

Publication number Publication date
ES2768718T3 (es) 2020-06-23
CA2948585C (en) 2022-07-26
KR102491556B1 (ko) 2023-01-25
JP2017516856A (ja) 2017-06-22
BR112016028085A2 (pt) 2017-08-22
US20170190731A1 (en) 2017-07-06
CY1122631T1 (el) 2021-03-12
HRP20200225T1 (hr) 2020-05-29
DK3626725T3 (da) 2023-02-27
JP6820253B2 (ja) 2021-01-27
US11117926B2 (en) 2021-09-14
CN106661079A (zh) 2017-05-10
RS64050B1 (sr) 2023-04-28
KR20170008767A (ko) 2017-01-24
CN110003301B (zh) 2022-06-10
LT3626725T (lt) 2023-03-10
MA39881B1 (fr) 2020-02-28
CN110003301A (zh) 2019-07-12
PT3626725T (pt) 2023-02-23
SMT202000070T1 (it) 2020-03-13
PT3149019T (pt) 2020-02-19
AU2015265893A1 (en) 2016-12-08
WO2015181275A8 (en) 2016-02-18
MX373721B (es) 2025-03-04
SMT202300057T1 (it) 2023-03-17
EP3149019A1 (en) 2017-04-05
HUE061506T2 (hu) 2023-07-28
SI3149019T1 (sl) 2020-03-31
DK3149019T3 (da) 2020-02-17
EP3626725B1 (en) 2022-11-30
MX2020004024A (es) 2021-12-10
CA2948585A1 (en) 2015-12-03
PH12016502327A1 (en) 2017-02-06
HUE048351T2 (hu) 2020-07-28
US20190352328A1 (en) 2019-11-21
SG11201609403UA (en) 2016-12-29
PL3626725T3 (pl) 2023-04-03
WO2015181275A1 (en) 2015-12-03
EP3626725A1 (en) 2020-03-25
EA032820B1 (ru) 2019-07-31
SI3626725T1 (sl) 2023-04-28
EA201692316A1 (ru) 2017-03-31
US10407462B2 (en) 2019-09-10
RS59910B1 (sr) 2020-03-31
SG10201809362RA (en) 2018-11-29
FI3626725T3 (fi) 2023-03-16
EP3149019B1 (en) 2019-12-04
HRP20230170T1 (hr) 2023-03-31
CN106661079B (zh) 2019-03-01
PL3149019T3 (pl) 2020-07-27
MX2016015724A (es) 2017-07-11
ES2938874T3 (es) 2023-04-17
AU2015265893B2 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
SG11201609403UA (en) Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
IL252596A0 (en) History of azabicyclooctane as fxr agonists for use in the treatment of liver and gastrointestinal diseases
IL247841A0 (en) Heterocyclic compounds for use in the treatment of disorders mediated by pi3k gamma
IL250663A0 (en) Gamma-diketones for the treatment and prevention of skin aging and wrinkles
HK1232120A1 (zh) 喹啉衍生物用於治療軟組織肉瘤的方法和用途以及用於治療軟組織肉瘤的藥物組合物
HRP20180260T1 (hr) Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja
SI3197556T1 (sl) Sestavek za preprečevanje in/ali zdravljenje alergijskih simptomov
IL251135A (en) A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
IL248381A0 (en) A combination of brexpiprazole and nalemapine and its use in the treatment of drug-related disorders
EP3223828A4 (en) Methods for the treatment and prevention of asbestos-related diseases
AU2014904751A0 (en) Methods for the treatment and prevention of asbestos-related diseases
AP2016009662A0 (en) Combination of taurine and racemethionine for treatment of liver diseases